NCT02339155 - Effect of Raxibacumab on Immunogenicity of Anthrax Vaccine Adsorbed | Biotech Hunter

Enrollment

573

Participants

Timeline

Start Date

February 24, 2015

Primary Completion Date

January 3, 2017

Study Completion Date

June 6, 2017

Conditions

Infections, Bacterial

Interventions

BIOLOGICAL

AVA

Sterile, milky-white suspension with dosage level of 0.5 mL for SC administration

BIOLOGICAL

Raxibacumab

Sterile, liquid formulation with unit dose strength of 40 mg/ kg for IV administration

DRUG

Diphenhydramine

Depending upon the labelling of the specific product chosen, 25 - 50 mg will be administered orally or IV

Trial Locations (3)

GSK Investigational Site, Edgewater

GSK Investigational Site, Knoxville

GSK Investigational Site, Overland Park